next message in archive
no next message in thread
previous message in archive
Index of Subjects
Tip Top Equities Late-September Issue Make no mistake: Our mission at Tip Top Equities is to sift through the thousands of underperforming companies out there to find the golden needle in the haystack. The micro-cap DIAMOND that can make you a fortune. More often than not, the stocks we profile show a significant increase in stock price, sometimes in days, not months or years. We have come across what we feel is one of those rare deals that the public has not heard about yet. Read on to find out more. Company: Ascentia Biomedical Symbol: ASCE . PK This company already gained 50% on Wednesday. We believe it is poised to go higher! Current price around : $0.90 Short Term Target Price: $1.90 12 month Target Price: $2.80 ***About the Company*** First, do a search on Acentia Biomedical with your favorite search engine. This is going to give you more detailed information than we are able to provide here. You will find that: Ascentia Biomedical Corporation's core business is the development of promising pharmaceutical families that have already undergone significant discovery, exploration and testing. The company seeks to strengthen its strategic and financial position by identifying additional indications for these compounds. Ascentia will search for additional products in order to diversify. New products emerge from in-house research focused on related compounds as well as through outright purchase or licensing. Products are also sourced throughout the world through the extensive network of the company's research team, particularly in the People's Republic of China. Additionally, promising products will be identified through contractual relationships. Ascentia will focus on therapies for two primary disease categories: +Immune-based diseases such as asthma and arthritis +Cancer ***Big news out for ASCE*** Ascentia Biomedical Receives $1 Million Funding Commitment to Support Continued Research and Organizational Growth BELLEVUE, WA. September 14, 2005 Ascentia Biomedical Corporation, a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research particularly in anti-cancer compounds and for organizational growth. The financing will come in the form of a series of separate convertible notes through Winsted Holdings Inc., Newport Beach, California, a highly respected Business Development Company. Dr. James Clagett, President & CEO of Ascentia Biomedical said, “This round of funding underscores the confidence and value Winsted has in our research and our exceptional scientific advisory board. It is a vote of confidence that further strengthens our efforts to provide the most comprehensive and cost-effective pharmaceutical research and development. This expansion round should position Ascentia to serve our customers with quality, innovative product solutions and efficacious pharmaceuticals.†The time to get in on this company is now. Big News is expected to move this company from "diamond in the rough" to "stellar performer". Watch this one trade all week! Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stoc.ks, securities must be understood as information provided and not investment advice. Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stoc.ks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the writer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say. Look at the news release by yourself and judge by yourself about the details in it.
next message in archive
no next message in thread
previous message in archive
Index of Subjects